低HER2乳腺癌患者的临床病理学特征和预后
1Breast Center, Department of Thyroid-Breast-Hernia Surgery, Department of General Surgery, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing, People's Republic of China.
BMC cancer
|September 28, 2023
概括
低人体表皮生长因子受体2 (HER2) 表达在HER2-阴性乳腺癌中很常见,并且与更好的无复发生存率有关,特别是在激素受体阳性和年轻患者中.
科学领域:
- 在瘤学瘤学.
- 分子诊断学 分子诊断
- 乳腺癌研究研究 乳腺癌研究
背景情况:
- 人体表皮生长因子受体2 (HER2) 的低表达,通过特定免疫组织化学 (IHC) 和现场杂交 (ISH) 标准来定义,代表了HER2-阴性乳腺癌的研究不足的子集.
- 了解低HER2表达的患病率和临床影响对于完善乳腺癌分类和治疗策略至关重要.
研究的目的:
- 确定在HER2阴性乳腺癌患者群体中低HER2表达的频率.
- 为了比较低HER2表达和零HER2表达的患者之间的临床病理学特征和预后结果 (无复发间隔和乳腺癌特异性存活率).
主要方法:
- 对684名原发性HER2阴性乳腺癌患者的回顾性分析,这些患者在2012年1月至2021年9月期间接受了手术.
- 数据收集包括临床病理特征,无复发间隔 (RFI) 和乳腺癌特定存活率 (BCSS).
- 在HER2-低和HER2-零 (IHC 0) 患者组之间使用Kaplan-Meier和多变量Cox回归分析进行了统计比较.
主要成果:
- 在74.9%的HER2阴性乳腺癌患者中发现了低HER2表达.
- 与HER2-零瘤相比,HER2-低瘤呈现出更高比例的激素受体 (HR) 阳性病例 (89.6%) 和较低的组织学III级 (29.4%).
- 低HER2表达与显著延长的RFI相关 (HR+的P=0.028,<65年的P=0.000),并被确定为RFI的低风险因素 (HR:0.531),但没有显著影响BCSS (P=0.272).
结论:
- 低HER2的乳腺瘤的特点是HR阳性的患病率较高,高组织学等级的发病率较低.
- 低HER2表达似乎是一个有利的预后因素,对无复发的存活率产生保护作用,特别是在HR阳性和年轻 (<65岁) 患者队列中.
- 需要对低HER2乳腺癌的治疗向进行进一步的研究.
更多相关视频
相关概念视频
01:21Cancer Survival Analysis
380
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
380
02:07Tumor Progression
6.4K
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
6.4K